Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual
Lyra Therapeutics (Nasdaq: LYRA) presented data from its Phase 2 LANTERN study of LYR-210, targeting chronic rhinosinusitis (CRS), at the Combined Otolaryngology Spring Meetings 2021. LYR-210 is a long-acting, non-invasive alternative for patients who failed medical management. The study showed significant improvement in both polyp and non-polyp patients, with 100% achieving minimal clinically important difference in symptoms. Key findings included a reduction in rescue medication use and improved imaging results. The data supports further development towards a pivotal Phase 3 trial.
- 100% of patients at the 7500µg dose achieved minimal clinically important difference (MCID) in SNOT-22 by week 24.
- Improvement in bilateral ethmoid Zinreich scores at week 24 (p=0.031) indicates disease modification.
- LYR-210 reduced the need for rescue treatment compared to control (p=0.048).
- Statistically significant improvement in 3CS composite score compared to control (p=0.003).
- None.
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today presented data from its Phase 2 LANTERN study of LYR-210, the company’s lead long-acting product candidate for chronic rhinosinusitis (CRS), at the Combined Otolaryngology Spring Meetings (COSM) 2021.
LYR-210 is an investigational product candidate designed to be administered in-office and to deliver a sustained release therapeutic for up to six months at difficult-to-access nasal inflammation sites, as a non-invasive alternative to surgery for patients who have failed medical management. Lyra reported positive topline data from the LANTERN study in December 2020.
The COSM oral presentation, titled Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study, contains the full 24-week data set from the company’s Phase 2 clinical trial of LYR-210. Previously unpublished data included: improvement from baseline in bilateral ethmoid Zinreich scores by magnetic resonance imaging (MRI); symptom improvement in both polyp and non-polyp patients; and the need for and use of rescue medication during the trial.
“The data presented today at COSM demonstrates LYR-210’s rapid and durable dose-dependent improvement based on several outcome measures, including the cardinal symptoms of CRS, SNOT-22, and MRI, in both non-polyp and polyp patients, from a single in-office administration,” said Professor Anders Cervin, Garnett Passe and Rodney Williams Memorial Foundation Chair in Otolaryngology at the University of Queensland, and a Principal Investigator for Lyra’s LANTERN trial. “Based on the results of the LANTERN trial, and my own experience with the drug candidate, I believe that LYR-210 has the potential to represent a major step forward in the care for CRS patients who are facing surgery as their next treatment option.”
Highlights from the Oral Presentation:
-
Polyp vs Non-Polyp Patients: Symptom improvement was observed in both polyp and non-polyp patients, with
100% of patients at the 7500µg dose in each group achieving the minimal clinically important difference (MCID) of 8.9 points for SNOT-22 total score by week 24, with a single administration of LYR-210. - Sinus Opacification: In the LANTERN study, subjects underwent paranasal sinus MRI at baseline as well as at the end of treatment. LYR-210 achieved improvement in bilateral ethmoid Zinreich scores (an objective measure of sinus opacification) at week 24 in a dose-dependent manner, providing evidence of disease modification, with the 7500µg dose achieving significant improvement compared to control between the two timepoints (p=0.031).
- Rescue Medication: Only 1 patient in the 7500µg group and 2 patients in the 2500µg group required a rescue treatment compared to 7 patients in the control group over the 24-week treatment period. The first incidence of rescue treatment in the control group occurred at week 2, while the only patient to require rescue treatment in the 7500µg group did not require rescue treatment until after week 18. As such, LYR-210 (7500µg) reduced the need for rescue treatment (p=0.048). The need for rescue treatment in the LANTERN study was determined by the treating physician.
Separately, Lyra has shared an analysis of the LANTERN study focused on a composite of three of the cardinal symptoms of CRS.
- Three Cardinal Symptoms: Lyra announced an analysis of a composite score of three cardinal symptoms (3CS) of CRS, which includes nasal blockage, nasal discharge and facial pain, which are the most prevalent symptoms for surgically naïve CRS patients both with and without nasal polyps. With a single administration, LYR-210 (7500µg) achieved statistically significant improvement in the 3CS composite score compared to control at week 24 (p=0.003) and at earlier timepoints.
A clinical presentation of the combined data announced today is available on Lyra’s website.
“We are delighted to present the full data set from our LANTERN study at COSM. I believe today’s data supports LYR-210’s ability to provide up to 24 weeks of effective symptom relief,” said Robert Kern, MD, Chief Medical Officer of Lyra Therapeutics. “LYR-210 is designed to provide continuous and consistent steroid treatment directly to diseased tissue and, additionally, eliminate patient compliance challenges. The additional data presented today shows that LYR-210 decreased ethmoid opacification and the need for rescue treatment in the LANTERN study, providing yet further evidence for LYR-210’s efficacy beyond the previously announced 4CS and SNOT-22 endpoints.”
“Our successful LANTERN study was designed to inform a pivotal Phase 3 trial for LYR-210, and today’s full data set has further shaped our thoughts regarding a preferred design for that trial, subject of course to an End-of-Phase 2 meeting with the FDA,” said Maria Palasis, Ph.D., President and Chief Executive Officer of Lyra Therapeutics. “In order to best address a combined polyp and non-polyp population, we are currently considering efficacy endpoints based on a composite 3CS of CRS score for our pivotal study, with the aim of bringing a much-needed new therapy to CRS patients as expeditiously as possible.”
About Lyra Therapeutics
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases. The company’s lead product candidate, LYR-210, is designed to deliver up to six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS) in patients who have not undergone surgery for the disease. Lyra is also developing LYR-220 for CRS patients who have undergone a prior surgery and have persistent disease. Beyond CRS, the company believes its
{
"@context": "https://schema.org",
"@type": "FAQPage",
"name": "Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual FAQs",
"mainEntity": [
{
"@type": "Question",
"name": "What is LYR-210 and its significance for chronic rhinosinusitis?",
"acceptedAnswer": {
"@type": "Answer",
"text": "LYR-210 is a long-acting investigational product designed to treat chronic rhinosinusitis by delivering sustained therapy over six months, providing a non-invasive alternative to surgery."
}
},
{
"@type": "Question",
"name": "What were the results of the LANTERN study for LYR-210?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The LANTERN study showed significant symptom improvement, with 100% of patients achieving MCID, and reduced need for rescue medication, indicating LYR-210's efficacy."
}
},
{
"@type": "Question",
"name": "What are the next steps for Lyra Therapeutics following the LANTERN study?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The company is planning a pivotal Phase 3 trial for LYR-210, focusing on a combined population of polyp and non-polyp patients."
}
},
{
"@type": "Question",
"name": "When was the LANTERN study data presented?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The data was presented at the Combined Otolaryngology Spring Meetings (COSM) 2021."
}
},
{
"@type": "Question",
"name": "What were the key findings presented at COSM 2021?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Key findings included significant symptom relief, improved MRI scores, and reduced need for rescue treatment in patients treated with LYR-210."
}
}
]
}
FAQ
What is LYR-210 and its significance for chronic rhinosinusitis?
What were the results of the LANTERN study for LYR-210?
What are the next steps for Lyra Therapeutics following the LANTERN study?
When was the LANTERN study data presented?
What were the key findings presented at COSM 2021?
